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Sphingolipid–protein interactionheir tendency to form laterally separated liquid-ordered phases, possess a high
potential for the creation of order in biological membranes. The formation of glycosphingolipid-rich
domains within the membrane has profound consequences on the membrane organization at different
levels, and on the conformational and biological properties of membrane-associated proteins and
multimolecular protein complexes. In this review, we will discuss 1) how glycosphingolipids inﬂuence
the lateral organization of biological membranes; 2) how glycosphingolipids inﬂuence the function of
membrane-associated proteins.
© 2008 Elsevier B.V. All rights reserved.Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
2. How do GSL inﬂuence the lateral organization of biological membranes? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185
3. How do GSL inﬂuence the function of membrane-associated proteins? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186
3.1. GM3 and EGF receptor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
3.2. GM3 and integrin receptors: the glycosynapse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
3.3. GM3 and insulin receptor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
3.4. Lactosylceramide and Lyn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
3.5. GM1 and Trk receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
4. The regulation of GSL composition of the plasma membrane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1911. Introduction
The notion that different levels of order exist in biological
membranes is deeply rooted in cellular biology. The ﬁrst level of
ordered organization is the creation of the lipid bilayer, a consequence
of the aggregational properties of complex amphipathic membrane
lipids. The lipid bilayer provides a physical boundary between the
cellular and extracellular environments, and a scaffold for moleculestor; GSL, glycosphingolipid(s);
in accordance with Svenner-
ochimica e Biotecnologie per la
Italy. Tel./fax: +390250330365.
inetti),
ll rights reserved.and molecular complexes that physically and functionally link these
two environments [3]. The lipid bilayer is characterized by several
basic properties that are relevant to its biological functions: the bilayer
as a whole is a very stable structure, however it allows its components
a certain degree of lateral motility. As a consequence of this ﬂuidity,
components of biological membranes can be arranged following a
non-homogenous lateral distribution, leading to the creation of
membrane areas (“domains”) with a highly differentiated molecular
composition and supermolecular architecture. The non-homogeneous
lateral distribution of membrane components is made possible by the
existence of lateral interactions stabilizing different membrane
domains, and creating a second level of order in the organization of
biological membranes. This level of order at the micron scale is
particularly evident in polarized cells, such as polarized epithelial cells
(where basolateral and apical membrane macrodomains can be
distinguished) and neurons (characterized by the presence of
somatodendritic, axonal and synaptic membrane macrodomains),
but morphologically distinct domains specialized for particular
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Membrane macrodomains are in general characterized by the
presence of speciﬁc subsets of proteins, and differential sorting and
trafﬁcking of proteins has been understood as one of the mechan-
isms responsible for the creation of polarized domains. In addition,
lateral heterogeneity in membrane structure is present also at the
sub-micron and nanometer scale, as indicated by the observation
that even in membrane regions lacking a morphologically distin-
guishable architecture, certain proteins cannot undergo a free and
continuous lateral diffusion, but rather are transiently conﬁned to
small domains (“microdomains”) [4]. Obviously limitations to
reciprocal diffusion are present for membrane proteins belonging
to a multiprotein complex, such as those organized around
membrane receptors or ion channels. More recently, to explain
these limitations in lateral diffusion, theories such as the “mem-
brane-skeleton fence” model have been proposed [5].
2. How do GSL inﬂuence the lateral organization of biological
membranes?
Protein–protein interactions have been regarded for several years
as the main factor responsible for the stabilization of membrane
macro- and microdomains. However, in the last 10 years a role for
membrane lipids in determining the lateral organization of the
membrane has emerged, and the concept that certain membrane
lipids, in particular glycosphingolipids (GSL), possess a high potential
for the creation of order in biological membranes, is now well
established [6]. Lipid membrane microdomains, or lipid rafts, areas in
the membrane different in lipid composition from other membrane
regions and characterized by a lateral organization dictated by the
properties of their lipid components, have been involved in an
incredible number of biological events [7–15]. However, the ability of
glycosphingolipids to inﬂuence the organization and function of other
components of biological membranes is still only partially understood,
and it might only in part depend on their tendency to segregate,
forming GSL-rich domains within the membrane. Lipid bilayers at
physiological temperature (that is above the melting temperature for
the most abundant glycerol- and sphingolipid molecular species)
usually exist in a liquid-disordered (ld) phase characterized by high
ﬂuidity, in which the lipid acyl chains are disordered and highly
mobile. Lowering the temperature below themelting point freezes the
lipid acyl chains in an ordered gel phase with very limited freedom of
movement. Membrane lipids can also exist in a third physical phase,
the liquid-ordered (lo) phase. In the lo phase, the acyl chains of lipids
are extended and ordered, as in the gel phase, but have higher lateral
mobility in the bilayer The lo phase is stabilized by the presence of
cholesterol, that ﬁll the hydrophobic gaps between the phospholipid
or glycolipid acyl chains [16,17]. The coexistence of lipids in different
phases within the same model membrane was probably the ﬁrst
evidence leading to the concept of lipid domains. GSL-rich domains
are likely more ordered than the ld phase, being in this regard similar
to a lo or a metastable gel phase. The earliest evidence supporting the
existence of lipid domains was obtained studying artiﬁcial membrane
models (including glycerophospholipid vesicles or liposomes contain-
ing glycosphingolipids, sphingomyelin, ceramide or/and cholesterol,
sphingolipid micelles, phospholipid bilayers on solid support, and
lipid monolayers on an air/water interface or on solid support).
Incomplete miscibility within a single phase, leading to lateral phase
separation of complex lipids in phospholipid bilayers can be observed
in binary mixtures of diacyl lecithins differing in chain length and/or
saturation [18–20] and in ternary mixtures of palmitoyloleyl PC,
dioleyl PC and cholesterol. However, sphingolipids, and GSL in
particular, strongly differ from glycerolipids for their molecular
structure and conformational properties (as discussed below), thus
leading to a strong tendency to segregate within phospholipid
bilayers. This tendency has been observed for non-glycosylatedsphingolipids (including ceramide and sphingomyelin), for a wide
range of neutral GSL molecular species, and for charged GSL, including
sulfatides and gangliosides (Reviewed in [17]). Sphingomyelin
undergoes lateral phase separation in dimyristoylphosphatidylcholine
bilayers, and separation of ceramide-rich phases in phospholipid
bilayers was observed for natural ceramides and for N-palmitoyl-
ceramide [20–24]. Comparing the behaviour of sphingomyelin and
ceramide with the same fatty acid chain, a stronger tendency of
ceramide for lateral phase separation, has been shown, suggesting
that the interconversion of sphingomyelin and ceramide (due to the
opposing actions of membrane-associated acid or neutral
sphingomyelinases, or sphingomyelin synthase 2) could be respon-
sible for rapid changes in the lateral organization of the membrane
[21,22].
Gangliosides form high molecular weight micelles [25] in diluted
aqueous solution. Using laser light scattering, the segregation of one
ganglioside component with respect to the other has been observed in
mixed micelles of two gangliosides with the same acyl chain but
different hydrophilic headgroups. This observation emphasizes the
importance of the geometrical properties of different GSL headgroups
as determinant for their segregative tendency [26,27]. Lateral
separation of gangliosides also occurs in one-component as well as
in two-component, two-phase phosphatidylcholine bilayers (dielai-
doylphosphatidylcholine: dipalmitoylphosphatidylcholine multila-
mellar liposomes, which exhibit laterally separated ﬂuid- and gel-
phase regions, more closely simulating the situation in biological
membranes) and in phospholipid bilayers in the presence of
cholesterol and/or sphingomyelin [28–37]. GM1-enriched domains
are also present in sphingomyelin bilayers and the formation of
separate GM1-enriched and cholesterol-enriched liquid-ordered
phases was observed [38] in ternary sphingomyelin/GM1/cholesterol
vesicles and in lipid monolayers (monomolecular lipid ﬁlms formed at
the air/water interface and transferred to silanized glass support)
prepared from mixtures of synthetic lipids as well as by natural cell
lipid extracts [39]. Thus, gangliosides display the ability to associate
with a pre-existing ordered domain or to segregate in their own
domains, that can be distinct from the cholesterol-enriched phase, as
conﬁrmed by the observation that the glycosynapse immunosepa-
rated from B16melanoma cells is enriched in GM3 ganglioside but not
in cholesterol [93].
All these data from the study of artiﬁcial membrane models
clearly demonstrate that sphingolipids form laterally separated
phases characterized by reduced ﬂuidity and hydrocarbon chain
mobility. In other words they have the tendency to form “clusters” in
ﬂuid lipid bilayers, as these segregated structures were originally
deﬁned, or “lipid rafts”, the term most widely used in the current
literature. Segregation of membrane sphingolipids is responsible for
the creation of less ﬂuid membrane regions, where membrane-
associated proteins can be conﬁned, favouring lateral interactions
between proteins that are segregated in the same lipid domain or
preventing interactions between proteins that are associated with
different domains. Moreover, proteins residing in sphingolipid- or
GSL-rich areas have a higher probability to laterally interact with the
conﬁning lipids.
This behaviour implies the existence of lateral cooperative interac-
tions between sphingolipid molecules. Again, studies conducted in
model membranes allowed to elucidate the chemical and physico-
chemical properties of sphingolipids that drive their lateral organiza-
tion as lipid membrane domains within biological membranes.
1) Due to the common hydrophobic ceramide backbone, all
sphingolipids are characterized by the presence of a planar, relatively
rigid system ranging from the amide group to the hydroxyl group on
C3 disposed at the water/lipid interface of the bilayer [40]. The
presence of an amide nitrogen, of a carbonyl oxygen and of a hydroxyl
group, confers to sphingolipids to act both as donors and acceptors for
the formation of hydrogen bonds [40]. This feature is unique for
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formation of each hydrogen bonds contributes 3–10 kcal to the
lipid–lipid interaction, while van der Waals forces between hydro-
carbon chains only contribute about 2–3 kcal per interaction, it is clear
that the formation of a hydrogen bond network at the water/lipid
interface strongly stabilizes the segregation of a rigid segregated
phase enriched in sphingolipids.
2) In the case of GSL, another factor favouring their segregation
within a biological membrane is represented by the presence of the
bulky oligosaccharide hydrophilic headgroup. Theoretical calculations
show that the volume occupied by the sugar GSL headgroup is much
larger than that occupied by phosphocholine, the bulkiest headgroup
present in phospholipids, requiring a bigger interfacial area to
accommodate the amphipathic molecule in the bilayer. Phase
separation with clustering of GSL in a phospholipid bilayer is a
spontaneous process driven by the minimization of the interfacial free
energy. The segregation of amphipathic molecules with a bulky
hydrophilic headgroup implies the acquisition of a positive membrane
curvature. The interfacial area increases with the size of the
oligosaccharide chain, with a corresponding more positive membrane
curvature and more pronounced segregation [25,41–52]. These
predictions based on the geometrical parameters of the GSLmolecules
are experimentally conﬁrmed by the observation that phase separa-
tion is present in mixed micelles of two gangliosides (GM2 and GT1b
[26], or GD1b and GD1b-lactone [27]) with the same fatty acid
composition and that the extent of ganglioside phase separation in
glycerophospholipid bilayers depend on the surface area occupied by
the GSL oligosaccharide chain, that is usually increasing with the
number of sugar residues [31–33].
It has been suggested that GSL clustering could be facilitated and
stabilised by the formation of carbohydrate–carbohydrate
interactions, i.e. hydrogen bonds involving the GSL sugar head groups.
Nevertheless, data proving evidence on direct side-by-side
oligosaccharide interactions are not available. In fact, NMR
spectroscopy on ganglioside micelles showed no NOE interactions
between isolated GSL molecules, that should indicate inter-monomer
carbohydrate–carbohydrate interactions [46]. In addition, no changes
in the carbohydrate chain conformation were detected as an effect of
the ganglioside-enriched environment. All this would exclude the
presence of signiﬁcant inter-molecular side-by-side interactions
capable of altering the “conformational information” carried by the
single saccharide chain of the ganglioside in the micellar model. This
could be due to the large amount of water present in the hydrophylic
layer [53]. Water is a natural component of the sugar shell being
attracted by the hydrophylic character of sugars and by the necessity
to avoid repulsion between the negative charged oligosaccharide.
Calculations performed on GM2micelles [26] indicated a difference of
about 5 Å between the dry and hydrated micellar radius, suggesting
that several molecules of water are interacting with the oligosacchar-
ide chains. This is in agreement with data from calorimetric studies
suggesting that each chain is surrounded by 40–70 water molecules
[54]. A strong interaction between water and GM1 sugars, sialic acid
and the inner galactose, was observed by NMR [46]. Water bridges
between saccharides have been observed in hyaluronan where they
were enough strong to determine and stabilize the tridimensional
structure of the molecule [55]. Of course these results and considera-
tions would exclude any direct inter-monomer side-by-side carbohy-
drate interactions at the level of cell membrane, but are in favor of a
speciﬁc role of water in organizing a net of hydrogen bonds able to
stabilized GSL clustering.
3) Membrane complex lipids, in particular glycerophospholipids,
are highly heterogeneous in their fatty acid composition, bearing acyl
chains with different number of carbon atoms and unsaturations. The
presence of glycerophospholipids with a high degree of unsaturation
ensures the membrane ﬂuidity that is a necessary requirement for the
functional properties of a biological membrane. The importance ofunsaturated lipids in this regard is emphasized by their high levels in
biological membranes from organisms adapted to life at extremely
low environmental temperatures. However, a certain portion of
complex lipids with saturated acyl chains is present inmany biological
membranes [56], and in some lipid classes, such as sphingomyelin and
gangliosides (at least in the nervous system), saturated acyl chains
(such as palmitic and stearic acid) are the main components. The
presence of saturated acyl chains (that can be tightly packed with a
high degree of order in the hydrophobic core of a bilayer) favours the
phase separation of a rigid, liquid-ordered phase. In dielaidoylpho-
sphatidylcholine: dipalmitoylphosphatidylcholine multilamellar lipo-
somes, the lateral separation of ﬂuid- and gel-phase regions has been
observed [18], and in general phase separation occurs in binary
mixtures of phosphatidylcholine molecular species differing in fatty
acid chain length and/or saturation [31–37]. In the case of GSL, for
GM1 it has been shown that distribution in the ﬂuid phase of a
phospholipid bilayer [35] is inversely correlated with the acyl chain
length and directly correlated with the degree of unsaturation. Very
long (≥C24) fatty acids are abundant in sphingolipids outside the
nervous system. In the skin stratum corneum, where unusually long
chain ceramides are the main lipid component, a high rigidity of the
lipid phase was observed, that is mainly present as a crystalline,
“solid” phase [57]. On the basis of neutron diffraction experiments on
artiﬁcial membranes, it has been proposed that the organization of
stratum corneum lipid bilayers could be highly stabilized by a partial
interdigitation between the two leaﬂets [58]. The case of skin lipids is
probably extreme, however a high concentration of C24 fatty acid
chains has been reported in LacCer from human neutrophils, and a
speciﬁc role of these long chain molecular species in the stabilization
of GSL-rich domains due to lateral interactions between interdigitated
hydrocarbon chains has been hypothesized [59,60]. Interdigitation of
long chain fatty acid residues of complex membrane lipids might thus
represent a further feature that favours the separation of liquid-
ordered phases. On the other hand, interdigitation potentially not only
inﬂuences the lateral organization of a single membrane leaﬂet, but
somehowmight be responsible for the tethering of the internal leaﬂet
to the external one, possibly explaining how properties of GSL-rich
domains present in the external leaﬂet might inﬂuence events
localized on the cytosolic side of the membrane.
3. How do GSL inﬂuence the function of membrane-associated
proteins?
As discussed in the previous section, segregation of membrane
sphingolipids leads to the creation of laterally separated liquid-ordered
phases that are less ﬂuid than the surrounding membrane environ-
ment. The great interest for lipid-rich membrane domains, that gave
rise to the complex and controversial discipline of raftology in the last
two decades, derived from the observation that some membrane-
associated proteins are highly concentrated in these domains, even if
the overall protein content of these membrane areas is very low. It has
been assumed that the trapping of certain proteins in lipid rafts might
be somehow functional to their biological role [61]. Studies on model
membranes, on detergent-resistant membrane fractions and in intact
cells indicated without doubt that several classes of membrane-
associated proteins display a strong preference for the association of
lipid-rich membrane domains (reviewed in [62]). Among most
common raft-targeting motifs are the presence of a GPI anchor
(sometimes modiﬁed by acylation of the inositol head group or by
replacement of the glycerolipid residue with ceramide) or of a lipid
modiﬁcation (tandemNH2 terminal myristoylation/palmitoylation and
double palmitoylation being especially efﬁcient signals for targeting to
lipid domains). Transmembrane proteins are in some cases also
concentrated in lipid rafts, although modelling of transmembrane
peptides indicated that in general targeting to liquid-ordered phases is
disfavoured. Thus, the presence of a lipidmodiﬁcation (palmitoylation)
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extracellular/cytoplasmic domains is required. Finally, peripheral
proteins can be associated or recruited to lipid rafts, possibly indirectly
via interactions with raft-resident proteins.
Anyway, as mentioned above, it has been suggested, and in some
cases proven, that the association with lipid-rich membrane domains
can inﬂuence the function of a membrane protein. The question is,
what are the mechanisms triggered by the association with lipid
domains, or with lipids within lipid domains, that can affect the
functional properties of a membrane protein. Several working
hypotheses can be done in this regard. 1) The association of a protein
with a liquid-ordered phase with reduced ﬂuidity with respect the
surrounding bilayer might represent a way to restrict the lateral
motility of the protein, thus favouring more stable interactions with
other proteins segregated in the same domains. In other words, the
association with lipid rafts could represent a mechanism to facilitate
the co-clustering of different membrane proteins. Against this
simplistic view it can be argued that the surface density of proteins
in lipid rafts is very low, and that in this case the limitations in lateral
motility could indeed hamper protein–protein interactions. On the
other hand, trapping of a protein within lipid rafts could prevent it
from interacting with other proteins preferentially localized in ﬂuid
membrane regions: raft association might thus have an inhibitory
signiﬁcance for biological events requiring protein–protein interac-
tions. 2) The association of a proteinwith a rigid membrane area could
induce conformational changes in the polypeptide chain affecting its
functional activity, independently from the formation of speciﬁc high
afﬁnity lateral interactions with other raft components. 3) Proteins
concentrated in lipid rafts are favoured in their interactions with lipid
components of the rafts. GSL, due to their complex oligosaccharide
groups, are good candidates for speciﬁc lipid–proteins lateral inter-
actions (it is worth to recall that trans interactions between the
hydrophilic head groups of GSL and proteins located on different
cellular membranes have been described [140]). Apart from the
association with lipid rafts, the ability of GSL, and gangliosides in
particular, to modulate the activity of membrane-associated proteins,
such as receptor tyrosine kinases, has been widely documented
(reviewed in [63,64]). Still to be elucidated in most cases remain the
molecular aspects of GSL–protein interactions underlying the mod-
ulatory effect of GSL. The oligosaccharide chain of a GSL inserted in the
plasma membrane could interact with a membrane protein via a)
aminoacid residues belonging to the extracellular loops of the protein,
if the conformation of the polypeptide chain allows them to be
sufﬁciently close to the membrane surface; b) sugar residues in the
glycans of a glycosylated protein, if the dynamics of the protein
oligosaccharide chain allows the correct orientation toward the cell
surface; c) the hydrophilic portion to the anchor in the case of GPI-
anchored proteins (that is surely located in proximity of the
extracellular surface of the membrane).
As mentioned above, early studies showed that many biological
effects of gangliosides can at least in part be due to the modulation of
several protein kinase systems [65–73]. The later observation that
receptor and non-receptor protein kinases are highly enriched in lipid
rafts suggested novel models for the interpretation of ganglioside-
mediated signal transduction. In the following part of this review, we
will describe some examples of protein functions inﬂuenced by the
association with a GSL or a GSL-rich microenvironment in the plasma
membrane.
3.1. GM3 and EGF receptor
Long time before the booming of raftology, the observation that
exogenously added GSL can inhibit the growth of cultured cells led to
the notion that the function of growth factor receptors can be
modulated by gangliosides [65]. Epidermal growth factor receptor
(EGFR) was identiﬁed as the target of the inhibitory action of GM3[74]. GM3 inhibited EGFR autophosphorylation without competing
with EGF for receptor binding [65,75,76], and without affecting
receptor dimerization [77]. Other gangliosides exert a much smaller
effect on EGFR, indicating the involvement of a highly speciﬁc
interaction [74,78]. Studies on the puriﬁed human recombinant
extracellular domain of EGFR indicated that the sialyllactose oligo-
saccharide is essential for ganglioside–receptor interaction, and that
the substitution with any other sugar negatively affects the binding
[78]. However, the molecular basis of this interaction has been only
recently fully elucidated, emphasizing the importance of side-by-side
carbohydrate–carbohydrate interactions between GM3 oligosacchar-
ide and a N-linked glycan bearing multiple GlcNAc terminal residues
on the receptor [79,80] (Fig. 1). GM3/EGFR interaction is facilitated by
the enrichment of EGFR in classical ganglioside-enriched, cholesterol-
sensitive, Triton X-100 insoluble membrane domains [81,82]. How-
ever, other GSL- and lipid raft-dependent factors can affect EGFR
function. Caveolae and caveolin-1 are involved in the modulation of
EGFR signalling [83,84] and EGFR is localized within a caveolin-rich
fraction in A431 cells. However, EGFR-containing membrane frag-
ments can be separated from caveolae [85,86]. In a keratinocyte-
derived cell line, GM3 overexpression induced a shift of caveolin-1 to
EGFR-rich membrane regions, allowing its functional interaction with
the EGFR receptor, that caused inhibition of EGFR tyrosine phosphor-
ylation and dimerization [87]. Thus, GM3 inﬂuences EGFR signaling by
a second distinct molecular mechanism modulating EGFR/caveolin-1
association. Moreover, GM3 negatively regulates as well the ligand-
independent cross-talk of EGFR with integrin receptor signaling,
disrupting when accumulated in cultured cells, the interaction of
integrin β1 subunit with EGFR [88].
3.2. GM3 and integrin receptors: the glycosynapse
The term “glycosynapse” has been introduced by S. Hakomori
[89–91] to describe a membrane microdomain involved in carbohy-
drate-dependent adhesion (through GSL–GSL interactions or through
GSL-dependent modulation of adhesion protein receptors, such as
integrins). Type 3 glycosynapses are Brij 98-insoluble, Triton X-100-
soluble [92] non-caveolar, cholesterol-independent GSL-rich mem-
brane domains characterized by the presence of tetraspanins (tetra-
spanmembraneprotein superfamilymembers), such as CD9, CD81 and
CD82. Tetraspanins are highly hydrophobic integral membrane
proteins with four transmembrane stretches, strongly interacting
with GSL [93]. On the other hand, tetraspanin associationwith integrin
receptors [94] has been described. Both tetraspanin CD9 and integrin
α3 orα5 receptor subunits are co-localized in glycosynapses (Fig. 2). In
cell lineswith high levels of GM3 ganglioside, CD9/integrin association
is positively modulated in a GM3-dependent fashion and a multi-
molecular complex between GM3, tetraspanin and integrin α3β1 or
α5β1 is stabilized, as shown by confocal microscopy and co-
immunoprecipitation experiments [95–97]. The formation of
integrin/CD9/GM3 complexes leads to the negative regulation of
integrin-mediated signal transduction cell adhesion and tumor cell
motility. In the presence of the GM3-dependent integrin/CD9 complex,
the c-Src kinase Csk, responsible for the phosphorylation of c-Src at
Tyr527, is translocated to the GSL-rich membrane domain with
consequent c-Src inactivation, leading to reduced cell motility [97].
Theseﬁndings indicate that integrin signalingmachinery ismodulated
by GSL-containing membrane complexes localized within
sphingolipid-enriched domains. Immunoseparated glycosynapses are
highly enriched in GM3 and sphingomyelin, but not in cholesterol [98]
(and glycosynapse-dependent signaling and tumor cellmotility are not
sensitive to cholesterol depletion [99]). The biological function of
glycosynapses in regulating integrin-dependent tumor cell motility
requires the presence of a speciﬁc GSL: exogenous addition of GM3, but
not of GM1, is able to enhance the reciprocal association ofα3 integrin
and CD9 [97], and, in a reconstituted glycosynapse membrane model,
Fig. 1. GM3 and EGFR. EGFR is activated upon ligand binding outside of lipid rafts. In the presence of high GM3 levels, EGFR activation, autophosphorylation and dimerization is
inhibited through a speciﬁc lateral interaction between the N-linked glycan of the receptor and the oligosaccharide chain of the ganglioside. Under these conditions, the shift of EGFR
to GSL- and caveolin-1-rich membrane domains occurs, favouring further regulation of EGFR activity by complexes with caveolin-1.
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but it was not when GM3 was replaced with structurally related GSL,
such as GM1, GD1a or LacCer [99], suggesting that a speciﬁc GSL–
protein interaction involving the sialyllactose oligosaccharide chain is
involved in glycosynapse-mediated signaling.
3.3. GM3 and insulin receptor
Insulin receptors (IR) are present in detergent-resistant mem-
branes from normal adipocytes [100] and localized in caveolae in
intact cells [101] (Fig. 3), where the β-subunit of IR interacts with
caveolin-1 through a binding motif recognizing the scaffold domain of
caveolin-1 [102]. Co-immunoprecipitation, cross-linking, ﬂorescence
microscopy and FRAP experiments showed that IR can form distinct
complexes with caveolin-1 and GM3 within lipid membrane domains
[103]. The interaction between GM3 and IR is direct (IR can be cross-
linked to a photoactivable GM3 derivative) and probably speciﬁc, since
it is abolished by the addition of exogenous GM3 in co-immunopre-
cipitation experiments. The lateral interaction between GM3 and IR
was abolished in IR mutants where the lysine residue at 944 was
replaced with arginine, valine, serine, or glutamine, suggesting that an
electrostatic interaction between the negatively charged sialyllactose
chain of GM3 and the positively charged amino group of lysine 944,
located in close proximity to the transmembrane domain sequence of
IR, is essential for the formation of the GM3/IR complex (Fig. 3). In3T3-L1 adipocytes, the induction of insulin resistance by treatment
with TNFα was accompanied by the upregulation of GM3 synthase,
leading to an increase of cellular GM3 [101,104], that accumulated in
detergent-resistant membranes. In insulin resistance, the association
of IR with GM3 was increased, while its association with caveolin-1
was decreased, indicating that the excess amount of GM3 in lipid
membrane domains leads to the displacement of IR from the complex
with caveolin-1 (Fig. 3), thus suggesting that the regulation of IR/
caveolin-1 by GM3 could be responsible for the changes in insulin
response in adipocytes [103].
3.4. Lactosylceramide and Lyn
Lactosylceramide (LacCer) is the most abundant GSL in human
neutrophils [105] and it has a relevant role in neutrophil physiological
functions [106,107]. LacCer on neutrophil cell surface binds several
pathogenic microorganisms, and anti-LacCer monoclonal antibodies
induce the phosphorylation of the Src family kinase with consequent
chemotaxis, phagocytosis and superoxide generation [106–108].
LacCer in human neutrophils is co-localized in a detergent-resistant
membrane fraction with Lyn [106] (Fig. 4), can be co-immunopreci-
pitated with Lyn and co-clusters at the cell surface with this protein
[59,60]. The very long fatty acid C24:0 and C24:1 chains were themain
components of LacCer (31.6% on the total fatty acid content) in the
detergent-resistant membrane fraction (DRM) from neutrophil
Fig. 2. GM3 and integrin receptors. In the glycosynapse, GM3 complexed with tetraspan
membrane proteins (CD9 or CD82) and integrin receptor subunits participate in the
control of cell motility. The GM3/CD9/integrin signaling complex formed in the
presence of high cellular GM3 levels inhibits cell motility by recruiting Src inhibitor, Csk,
thus keeping Src in a less active state.
Fig. 4. LacCer and Lyn. In human neutrophils, Lyn is enriched in C24-LacCer-enriched
domains and physically interacting with C24-LacCer, likely via van der Waals
interactions between the LacCer hydrocarbon chains and those of Lyn. Lyn coupling
with C24-LacCer is required for LacCer-mediated signal transduction, leading to
superoxide generation, chemotaxis and phagocytosis.
189A. Prinetti et al. / Biochimica et Biophysica Acta 1788 (2009) 184–193plasma membranes [59,60]. Dimethyl sulfoxide (DMSO)-treated
neutrophilic differentiated human promyelocytic leukemia HL-60
cells (D-HL-60 cells), an experimental model for the study ofFig. 3. GM3 and insulin receptor. In insulin-resistant adipocytes, GM3 synthesis is upregulate
the displacement of IR from the complex with caveolin-1 to the complex with GM3, inh
sialyllactose chain of GM3 and lysine 944 in IR is required for the formation of the GM3/IRneutrophil function, are not able to respond with chemotaxis and
superoxide generation to anti-LacCer antibodies, nor to phagocytose
non-opsonized zymosans. As in neutrophils, LacCer is the main GSL in
D-HL-60 cells, and it is enriched in detergent-resistant membrane, but
it does not co-localizewith Lyn. Themain difference between D-HL-60
cells and neutrophils was found in the fatty acid composition of
LacCer: in D-HL-60 cells, over 70% of LacCer in detergent-resistant
membranes contains palmitic acid, and only 13.6% is represented byd and the consequent accumulation of GM3 in detergent-resistant membranes induces
ibiting the downstream signal transduction. An electrostatic interaction between the
complex.
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homogeneous LacCer molecular species, the added species became
components of the detergent-resistant membrane fraction without
affecting the overall LacCer cellular content. Loading with C24:0 or
C24:1-LacCer, but not with shorter chain species, conferred to D-HL-
60 cells the ability to migrate and to generate superoxides in
response to anti-LacCer antibody [59,60], and induced CD11b/CD18-
dependent phagocytosis of non-opsonized zymosans [108]. More-
over, in C24-LacCer loaded D-HL-60 cells, LacCer associated and
clustered together with Lyn, suggesting that LacCer species with very
long fatty acids are speciﬁcally necessary for the formation of
membrane complexes and the functional coupling with Lyn. The
physical and functional coupling of LacCer with Lyn could be due to
direct van der Waals interactions between the GSL acyl chains (that,
in the case of C24-containing species, are longer than the half
hydrophobic thickness of the membrane bilayer) and those of Lyn.
However, the sugar chain of LacCer also plays a relevant role in this
interaction, since the addition of C24-GM1 did not affect the
biological properties of D-HL-60 cells.Fig. 5. Regulation of sphingolipid-enriched membrane domain composition by phosphoryla
interconversion of ceramide and sphingomyelin due to the action of plasma-membrane resid
of the sphingolipid-enriched membrane domains. In particular, ceramide generation can lead
small membrane domains into large ceramide-rich signaling platform [156]. GSL compositi
Neu3, and probably by membrane-resident glycosyltransferases, leading to changes in the g
interactions.3.5. GM1 and Trk receptors
Pioneering works on ganglioside biology indicated that ganglio-
series structures, the most represented in the nervous system, possess
neuritogenic and neuronotrophic properties [109,110]. In particular for
GM1, one of the main gangliosides in brain and neurons, many pieces
of evidence, mainly based on the exogenous administration of this
GSL, indicated that it exerts a positive effect on neuronal growth,
differentiation and survival both in vivo and in cultured neurons, and a
protective effect against neuronal injury, thus acting as a neurotrophic
factor [111–114]. With its pleiotropic effect, GM1 in neurons seems to
potentiate or to replace neurotrophins in their action [115]. This
suggests that the GM1 neurotrophic effect could be mediated by Trk
neurotrophin receptors. Indeed, early studies in PC12 cells showed
that exogenous GM1 can stimulate Trk kinase activity, receptor
autophosphorylation and dimerization [113,116], and that GM1 can
speciﬁcally and tightly bind Trk [117]. The ability of GM1 (alone or in
combination with neurotrophins) to activate TrkA, TrkB and TrkC
receptors has been conﬁrmed in other cell types [118–120], in braintion/dephosphorylation (“sphingomyelin cycle”) and glycosylation/deglycosylation. The
ent sphingomyelinases and sphingomyelin synthase 2 leads to profound reorganization
to changes in the membrane curvature and vesiculation, or to the fusion of pre-existing
on can be regulated by desialylation due to the plasma membrane-associated sialidase
eometry and organization of GSL-rich membrane domains and in speciﬁc GSL–protein
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receptors has been found to be associated with lipid rafts [124–129],
and at least TrkB can be translocated to detergent-insoluble
membranes from other cellular compartments upon stimulation
with BDNF [124,125], suggesting that the receptor localization within
GSL-rich membrane areas can be relevant for the regulation of their
function. The ganglioside-speciﬁc, plasma membrane-associated
Neu3 sialidase is abundantly expressed in the cerebral cortex and in
the cerebellum [130], and at the subcellular level is enriched in lipid
rafts [131], together with its putative substrates, polysialoganglio-
sides. The activation of Neu3 might represent an efﬁcient mechanism
to locally increase the GM1 concentration, thus affecting Trk activity.
In rat neurons, local activation of TrkA downstream to the action of
Neu3 is essential in determining axon speciﬁcation [132], and
modulation in a positive or negative sense of Neu3 expression deeply
affects neuritogenesis [133,134]. The extracellular portion of the
receptor is essential for GM1-induced activation [120], and the
glycosylation of Trk is required for the formation of Trk–GM1
complexes and for the targeting of Trk into GM1-enriched domains
[135], suggesting that glycosylation could be a physiologically relevant
mechanism for the regulation of Trk trafﬁc and function, and that
lateral interactions between the oligosaccharide chains of the receptor
and of GM1 are responsible for receptor ﬁne tuning. However, this
hypothesis is challenged by some experimental observations, indicat-
ing that other mechanisms might be at least in part responsible for
GM1 neurotrophic effect: 1) it remains to be elucidated whether GM1
treatment is able or not to induce the release of neurotrophins,
triggering an autocrine loop in Trk receptor regulation. Rabin et al.
showed that exogenous GM1 is able to induce the release of
neurotrophin-3 (but not of other neurotrophins) from cultured
ﬁbroblasts and cerebellar granule cells [120]. On the other hand, no
efﬂux of NGF, BDNF and NT3 has been observed upon incubation of
slices from different brain regions with GM1 [121,122]. 2) GM1-
induced neuritogenesis has been observed also in neurotumor cell
lines (such as Neuro2a neuroblastoma cells) non responsive to NGF
and lacking the expression of both high- and low-afﬁnity NGF
receptors [136,137]. In these cells, the neuritogenic effect of GM1
and other gangliosides seems to be linked to the activation of the non-
receptor tyrosine kinase c-Src, highly enriched in GSL-rich membrane
domains. 3) In neuroblastoma cells and in brain slices, signal
transduction is triggered upon very short treatment with GM1.
Under the experimental conditions used in these latter studies, GM1
remains loosely associated with the plasma membrane, with little or
no serum- and trypsin-stable GM1 [116,132]. This would suggest that
GM1 can interact with the exoplasmic portion of the receptor and
trigger its activation without the need to be inserted in the same
membrane, arguing against the involvement of lateral interactions
between the GSL and the receptor [121,137]. 4) It has been shown that
PC12 cells, the main cellular model used for the characterization of
Trk-dependent GM1-induced signal transduction, indeed express
little or no GM1, but high amounts of fucosylGM1. Thus, the possible
role of fucosylGM1, and not GM1, as the endogenous modulator of Trk
activity deserves further investigation [138].
4. The regulation of GSL composition of the plasma membrane
Clearly, according to the scenario described in the previous
paragraphs, changes in the GSL composition of the plasma membrane
in a certain cell type would lead to very important biological
consequences, thus all mechanisms possibly contributing to these
changes have a high functional signiﬁcance. The classical view on
sphingolipid metabolism implies the vesicular transport of neobio-
synthesized sphingolipids from the endoplasmic reticulum and the
Golgi apparatus to the plasma membranes (reviewed in [139]).
Changes in the activities of enzymes of the biosynthetic pathway
have been associated with the changes in GSL expression that areassociated with biological events such as neoplastic transformation or
neuronal differentiation. However, other mechanisms could be
responsible for a local regulation of the GSL composition of plasma
membranes or restricted plasma membrane areas (Fig. 5). 1) Both
catabolic and biosynthetic enzymes for sphingolipids have been found
associated with the plasma membranes. “Signalling” sphingomyeli-
nases are resident in or translocated to the plasma membrane, being
able to convert plasma membrane sphingomyelin into ceramide
[140,141]. Conversely, a plasma membrane-associated sphingomyelin
synthase enzyme activity (SMS2), genetically distinct from the Golgi
enzyme, has been identiﬁed [142]. Thus, the sphingomyelin/ceramide
ratio can be locally modulated possibly in response to physiological
events, leading to profound consequence on the organization of
sphingolipid-enriched membrane areas. In the case of GSL, a speciﬁc
membrane-bound sialidase (Neu3) has been identiﬁed and cloned
[130,143,144], and its role in modifying the ganglioside composition at
the cell surface, acting as well on GSLmolecules present on the surface
of adjacent cells (i.e., in a “trans” fashion), has been proven
[131,145,146]. Moreover, the presence of sialyltransferase activities at
the cell surface has been also reported [147–151], Thus, glycosylation/
deglycosylation cycles might be very important mechanisms respon-
sible for rapid and possibly transient changes of the plasma
membrane GSL composition, in analogy to that proposed for the
“sphingomyelin cycle”. The presence of other active glycosylhydro-
lases, β-glucosidase, β-galactosidase and β-hexosaminidase [146,152],
in the plasma membrane has been demonstrated, implying that local
hydrolysis of GSL at the cell surface might represent a general
mechanism for the control of GSL composition. 2) GSL can be released
from the cell surface in different forms, including shedding vesicles
[153–155], whose controlled release from speciﬁc glycolipid-enriched
membrane areas, could represent a further way to modify the lipid
membrane domain composition and organization.
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